SC
BCAX

Steven Cohen’s Bicara Therapeutics BCAX Stock Holding History

Steven Cohen’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,138
Closed -$476K – 4242
2025
Q3 		$476K Sell
30,138
-186,698
-86% -$2.09M ﹤0.01% 1942
2025
Q2 		$2.01M Buy
+216,836
New +$2.58M ﹤0.01% 1299
2024
Q4 		– Sell
-371,962
Closed -$9.47M – 2543
2024
Q3 		$9.47M Buy
+371,962
New +$9.49M 0.02% 664

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Steven Cohen's BCAX Position: Q4 2025 in Review

Steven Cohen sold out of Bicara Therapeutics (BCAX) in Q4 2025, closing a stake of 30,138 shares — an estimated $476K sold.

Steven Cohen first reported a position in BCAX in Q3 2024 and held it in 3 quarters. The position peaked at $9.47M in Q3 2024. 140 funds tracked by Wall St. Rank hold BCAX as of Q4 2025.

  • Steven Cohen reported no remaining Bicara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Steven Cohen sold 30,138 Bicara Therapeutics shares in Q4 2025, an estimated $476K.
  • Steven Cohen first reported a position in Bicara Therapeutics in Q3 2024 and held it in 3 quarters.
  • Steven Cohen's Bicara Therapeutics position peaked at $9.47M in Q3 2024.
  • 140 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.